Experimental drug tarlatamab takes on rare, Tough-to-Treat cancer
NCT ID NCT06893783
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a drug called tarlatamab in 60 adults with advanced extrapulmonary neuroendocrine carcinoma, a rare cancer that has come back after standard chemotherapy. Tarlatamab works by helping the body's immune cells find and attack cancer cells. The main goal is to see if the drug can shrink tumors, with secondary goals of slowing disease progression and improving survival. There is no placebo group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tarlatamab (a drug that helps immune cells attack cancer cells)
What this could lead to
If successful, this could offer a new treatment option for people with advanced neuroendocrine carcinoma that has stopped responding to standard chemotherapy.
What could go wrong
This is an early-phase trial with only 60 participants and no comparison group. The drug may not shrink tumors or improve survival, and side effects could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE CARCINOMAS (NEC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Samsung Medical Center
NOT_YET_RECRUITINGSeoul, South Korea
Contact Email: •••••@•••••
-
Seoul National University Hospital
RECRUITINGSeoul, South Korea
Contact Email: •••••@•••••
-
Yonsei Severance Hospital
NOT_YET_RECRUITINGSeoul, South Korea
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.